Volume 29, issue 3, March 2022
130 articles in this issue
1. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
2. Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: PRODIGE 23 Trial
3. Too Many or Too Few? How Many Lymph Nodes Are Enough?
4. Biomarker-Driven Prognostication in Merkel Cell Carcinoma: A Paradigm for Personalized Therapy
5. Editorial: Impact of the Covid-19 Pandemic on Breast Cancer Treatment and Patient Experience
6. Communication is the Key to an Improved Patient Experience When it Comes to Surgical Delays
7. Removing Barriers to Access Starts with a Phone Call: Impact of Pre-Visit Coordination of Care in Efficiency of Therapy and Patient and Provider Satisfaction
8. The Importance of Clinical Decision-Making in Surgical Planning for Non-Small Cell Lung Cancer
9. Chest CT-Derived Muscle Metrics for Sarcopenia: Choosing the Right Target
10. The Paradox of Early Stage Rectal Cancer: More ReSeARCh in the Right Direction
11. Cost-Effectiveness of Watch and Wait: What is in the Box of this Organ-Preservation Strategy?
12. Access to Colorectal Cancer Care for Medicaid-Insured Patients at Designated Cancer Facilities
13. Association of Liberal Fluid Therapy for Colorectal Cancer Surgery and Long-Term Oncologic Recurrence
14. Is Axillary Radiation not Inferior to Axillary Dissection for Sentinel Lymph Node-Positive Breast Cancer After Neoadjuvant Chemotherapy?
15. Surgical Excision Versus Neoadjuvant Radiotherapy Followed by Delayed Surgical Excision of Ductal Carcinoma In Situ (NORDIS)
16. Preoperative Use of a Radiation Boost to Enhance Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer
17. A Novel Criterion for Lymph Nodes Dissection in Distal Pancreatectomy for Ductal Adenocarcinoma: A Population Study of the US SEER Database
18. ASO Author Reflections: Lymphadenectomy in Distal Pancreatectomy for Ductal Adenocarcinoma: How to Do Better?
19. Landmark Series: Importance of Pancreatic Resection Margins
20. ASO Author Reflections: Pancreatic Resection Margins—Chasing Moons
21. Sarcopenia as a Predictor of Survival in Patients with Pancreatic Adenocarcinoma After Pancreatectomy
22. ASO Visual Abstract: Sarcopenia as a Predictor of Survival in Patients with Pancreatic Adenocarcinoma After Pancreatectomy
23. Determining Hospital Volume Threshold for Safety of Minimally Invasive Pancreaticoduodenectomy: A Contemporary Cutpoint Analysis
24. ASO Author Reflections: An Objective Hospital Volume Threshold for Minimally Invasive Pancreaticoduodenectomy
25. ASO Visual Abstract: Determining Hospital Volume Threshold for the Safety of Minimally Invasive Pancreaticoduodenectomy: A Contemporary Cutpoint Analysis
26. Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
27. ASO Author Reflections: Neoadjuvant Chemotherapy Switch: Optimizing Neoadjuvant Treatment Sequencing in Pancreas Cancer
28. ASO Visual Abstract: Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
29. Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy Followed by Pancreatectomy
30. ASO Visual Abstract: Circulating Tumor DNA as a Potential Prognostic Marker in Patients with Borderline-Resectable Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy Followed by Pancreatectomy
31. Distinct Survival Outcomes in Subgroups of Stage III Pancreatic Cancer Patients: Taiwan Cancer Registry and Surveillance, Epidemiology and End Results registry
32. ASO Author Reflections: Identification of Prognostic Factors for Stage-III Pancreatic Ductal Adenocarcinoma patients.
33. ASO Visual Abstract: Distinct Survival Outcomes for Subgroups of Stage 3 Pancreatic Cancer Patients: Taiwan Cancer Registry and Surveillance, Epidemiology, and End Results Registry
34. Merkel Cell Polyomavirus Antibody Titer Predicts Recurrence-Free Survival
35. ASO Author Reflections: The Evolving and Expanding Role of Merkel Cell Polyomavirus Antibody Titers
36. COVID-19 is Affecting the Presentation and Treatment of Melanoma Patients in the Northeastern United States
37. ASO Visual Abstract: COVID-19 is Affecting the Presentation and Treatment of Melanoma Patients in the Northeastern United States
38. External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort
39. ASO Author Reflections: Validation of Prediction Model for Response to Treatment with T-VEC
40. ASO Visual Abstract: External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort
41. Patient Perceptions of Changes in Breast Cancer Care and Well-Being During COVID-19: A Mixed Methods Study
42. ASO Visual Abstract: Patient Perceptions of Changes in Breast Cancer Care and Well-Being During COVID-19: A Mixed-Methods Study
43. Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision
44. ASO Visual Abstract: Atypical Lobular Hyperplasia and Classic Lobular Carcinoma In Situ Can Be Safely Managed Without Surgical Excision
45. Comparison of Outcomes for Classic-Type Lobular Carcinoma In Situ Managed with Surgical Excision After Core Biopsy Versus Observation
46. ASO Author Reflections: Observation After a Core Biopsy Diagnosis of Classic-Type LCIS Is a Safe Standard of Practice
47. ASO Visual Abstract: Comparison of Outcomes for Classic-Type Lobular Carcinoma In Situ Managed with Surgical Excision After Core Biopsy Versus Observation
48. Neoadjuvant Endocrine Therapy and Delays in Surgery for Ductal Carcinoma in Situ: Implications for the Coronavirus Pandemic
49. ASO Author Reflections: Neoadjuvant Endocrine Therapy: A Pill in Time Saves Nine
50. ASO Visual Abstract: Neoadjuvant Endocrine Therapy and Delays in Surgery for Ductal Carcinoma in Situ: Implications for the Coronavirus Pandemic
51. Timing of Presentation and Outcomes of Women with Stage IV Pregnancy-Associated Breast Cancer (PABC)
52. ASO Author Reflections: Stage IV Pregnancy-Associated Breast Cancer: A Continuum of Disease
53. ASO Visual Abstract: Timing of Presentation and Outcomes of Women with Stage IV Pregnancy-Associated Breast Cancer (PABC)
54. A Single-Center Study of Adherence to Breast Cancer Screening Mammography Guidelines by Transgender and Non-Binary Patients
55. ASO Author Reflections: Constructing a Transgender and Nonbinary Cohort to Analyze Breast Cancer Screening
56. ASO Visual Abstract: A Single Center Study of Adherence to Breast Cancer Screening Mammography Guidelines by Transgender and Non-Binary Patients
57. Health-Related Quality of Life After Nipple-Sparing Mastectomy: Results From the INSPIRE Registry
58. ASO Visual Abstract: Health-Related Quality of Life After Nipple-Sparing Mastectomy: Results from the INSPIRE Registry
59. Association Between Local Anesthetic Dosing, Postoperative Opioid Requirement, and Pain Scores After Lumpectomy and Sentinel Lymph Node Biopsy with Multimodal Analgesia
60. ASO Author Reflection: Pain Control Can Be Optimized with Surgeon-Administered Local Anesthesia in Patients Undergoing Lumpectomy and Sentinel Lymph Node Biopsy with Multimodal Analgesia
61. ASO Visual Abstract: Association Between Local Anesthetic Dosing, Postoperative Opioid Requirement, and Pain Scores After Lumpectomy and Sentinel Lymph Node Biopsy With Multimodal Analgesia
62. How to Perform Repeat Sentinel Node Biopsy Safely After a Previous Mastectomy: Technical Features and Oncologic Outcomes
63. ASO Author Reflections: Value of Sentinel Node Biopsy for Chest Wall Recurrence After Mastectomy
64. Is Medicaid Expansion Narrowing Gaps in Surgical Disparities for Low-Income Breast Cancer Patients?
65. ASO Author Reflections: Medicaid Expansion is Key in Mitigating Surgical Disparities in Low-Income Breast Cancer Patients
66. ASO Visual Abstract: Is Medicaid Expansion Narrowing Gaps in Surgical Disparities for Low-Income Breast Cancer Patients?
67. Diagnostic Accuracy of Nipple Discharge Fluid Cytology: A Meta-Analysis and Systematic Review of the Literature
68. ASO Reflection: Diagnostic Accuracy of Nipple Discharge Fluid Cytology: A Meta-Analysis and Systematic Review of the Literature
69. Enhanced PAtient Clinical Streamlining (EPACS): Quality Initiative to Improve Healthcare for New Surgical Outpatient Visits
70. New Operative Reporting Standards: Where We Stand Now and Opportunities for Innovation
71. ASO Visual Abstract: Enhanced PAtient Clinical Streamlining (EPACS)—Quality Initiative to Improve Healthcare for New Surgical Outpatient Visits
72. Non-Small-Cell Lung Cancer Patients with a High Predicted Risk of Irradical Resection: Can Chemoradiotherapy Offer Similar Survival?
73. ASO Visual Abstract: Non-small Cell Lung Cancer Patients with a High Predicted Risk of Irradical Resection—can Chemoradiotherapy Offer Similar Survival?
74. Combination of Skeletal Muscle Mass and Density Predicts Postoperative Complications and Survival of Patients With Non-Small Cell Lung Cancer
75. ASO Author Reflections: An Evolving Skeletal Muscle Profiling—Towards Precise Host Phenotype and Prognostic Stratification in Non-small Cell Lung Cancer
76. ASO Visual Abstract: Combination of Skeletal Muscle Mass and Density Predicts Postoperative Complications and Survival of Patients with Non-small Cell Lung Cancer
77. Pleural Invasion Depth of Disseminated Nodules in Patients with Stage IVa or Recurrent Thymoma: Assessment, Curative Impact, and Surgical Outcomes
78. ASO Visual Abstract: Pleural Invasion Depth of Disseminated Nodules in Patients with Stage IVa or Recurrent Thymoma: Assessment, Curative Impact, and Surgical Outcomes
79. Multimodal Prehabilitation During Neoadjuvant Therapy Prior to Esophagogastric Cancer Resection: Effect on Cardiopulmonary Exercise Test Performance, Muscle Mass and Quality of Life—A Pilot Randomized Clinical Trial
80. ASO Author Reflections: A Randomized Controlled Trial to Address the Effect of Prehabilitation During Neoadjuvant Therapy on Cardiopulmonary Fitness, Muscle Mass and Quality of Life in the Oesophagogastric Cancer Patient
81. C-Reactive Protein and C-Reactive Protein-Based Scores to Predict Survival in Esophageal and Junctional Adenocarcinoma: Systematic Review and Meta-Analysis
82. ASO Visual Abstract: C-Reactive Protein and C-Reactive Protein-Based Scores to Predict Survival in Esophageal and Junctional Adenocarcinoma: Systematic Review and Meta-analysis
83. Comparison Between Wedge Resection and Lobectomy/Segmentectomy for Early-Stage Non-small Cell Lung Cancer: A Bayesian Meta-analysis and Systematic Review
84. Rectal Sparing Approach After Neoadjuvant Therapy in Patients with Rectal Cancer: The Preliminary Results of the ReSARCh Trial
85. ASO Author Reflections: Rectal Preservation After Major or Complete Clinical Response to Neoadjuvant Therapy—The Safety of Integrated Approaches
86. ASO Visual Abstract: Rectal Sparing Approach After Neoadjuvant Therapy in Patients with Rectal Cancer: The Preliminary Results of the ReSARCh Trial
87. Cost Effectiveness of Watch and Wait Versus Resection in Rectal Cancer Patients with Complete Clinical Response to Neoadjuvant Chemoradiation
88. ASO Author Reflections: Bang for Your Buck—Implications of the Cost-Effectiveness of Watchful Waiting Versus Radical Surgery for Locally Advanced Rectal Cancer After Successful Neoadjuvant Chemoradiation
89. Laparoscopic Versus Robot-Assisted Versus Transanal Low Anterior Resection: 3-Year Oncologic Results for a Population-Based Cohort in Experienced Centers
90. ASO Visual Abstract: Laparoscopic Versus Robot-Assisted Versus Transanal Low Anterior Resection: 3-Year Oncologic Results of a Population-Based Cohort in Experienced Centers
91. Healthcare Costs of Laparoscopic versus Open Surgery for Rectal Cancer Patients in the First 12 Months: A Secondary Endpoint Analysis of the Australasian Laparoscopic Cancer of the Rectum Trial (ALaCaRT)
92. ASO Author Reflections: Is laparoscopic-Assisted Surgery More Costly than Traditional Open Resection for Rectal Cancer Treatment?
93. ASO Visual Abstract: Health Care Costs of Laparoscopic Versus Open Surgery for Rectal Cancer Patients in the First 12 Months: A Secondary End-Point Analysis of the Australasian Laparoscopic Cancer of the Rectum Trial (ALaCaRT)
94. Management of Colorectal Cancer with Synchronous Liver Metastases: An Inception Cohort Study (CoSMIC)
95. Outcomes of Combined Peritoneal and Local Treatment for Patients with Peritoneal and Limited Liver Metastases of Colorectal Origin: A Systematic Review and Meta-Analysis
96. ASO Visual Abstract: Outcomes of Combined Peritoneal and Local Treatment in Patients with Peritoneal and Limited Liver Metastases of Colorectal Origin: A Systematic Review and Metaanalysis
97. Adrenocortical Carcinoma: The Value of Lymphadenectomy
98. ASO Author Reflections: Adrenocortical Carcinoma—All We Need Are Nodes
99. ASO Visual Abstract: Adrenocortical Carcinoma—The Value of Lymphadenectomy
100. Bilateral Central Neck Dissection via Transoral Approach in Papillary Thyroid Carcinoma
101. ASO Author Reflections: Central Neck Dissection Can Be Performed Via Transoral Approach
102. Diagnostic Performance of Artificial Intelligence-Centred Systems in the Diagnosis and Postoperative Surveillance of Upper Gastrointestinal Malignancies Using Computed Tomography Imaging: A Systematic Review and Meta-Analysis of Diagnostic Accuracy
103. ASO Author Reflections: Applications of Artificial Intelligence in Oesophago-Gastric Malignancies—Present Work and Future Directions
104. ASO Visual Abstract: Diagnostic Performance of Artificial Intelligence-Centered Systems in the Diagnosis and Postoperative Surveillance of Upper Gastrointestinal Malignancies Using Computed Tomography Imaging: A Systematic Review and Meta-Analysis of Diagnostic Accuracy
105. Malignant Bowel Obstruction Management Over Time: Are We Doing Anything New? A Current Narrative Review
106. Carcinomatosis in Early-Stage Cervical Cancer Treated with Robotic Radical Hysterectomy: Recurrence Patterns, Risk Factors, and Survival
107. ASO Visual Abstract: Carcinomatosis in Early-Stage Cervical Cancer Treated with Robotic Radical Hysterectomy—Recurrence Patterns, Risk Factors, and Survival
108. Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma
109. ASO Author Reflections: Neoadjuvant Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, Fluorouracil, and Leucovorin Is an Incredible Helper in Curing Patients with Intermediate-Advanced-Stage and Technically Resectable Hepatocellular Carcinoma
110. ASO Visual Abstract: Comparison between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate/Advanced-Stage Hepatocellular Carcinoma
111. Laparoscopic in Situ Anatomical Mesohepatectomy for Solitary Massive HCC Using Combined Intrafascial and Extrafascial Approaches With Indocyanine Green Navigation (with Video)
112. ASO Author Reflections: Laparoscopic in situ Anatomical Mesohepatectomy for Solitary Massive HCC Using Combined Intrafascial and Extrafascial Approaches with Indocyanine Green Navigation: A New Era of Digital Intelligent Liver Surgery
113. ASO Visual Abstract: Laparoscopic in Situ Anatomical Mesohepatectomy for Solitary Massive HCC Using Combined Intrafascial and Extrafascial Approaches with Indocyanine Green Navigation (with Video)
114. Timing of Primary Tumor Resection in Synchronous Metastatic Colon Cancer Patients Undergoing Hepatic Arterial Infusion Pump Placement
115. ASO Author Reflections: Hepatic Arterial Infusion Pump Can Be Placed Simultaneously with Primary Tumor Resection in Colon Cancer Patients with Synchronous Metastases
116. ASO Visual Abstract: Timing of Primary Tumor Resection in Synchronous Metastatic Colon Cancer Patients Undergoing Hepatic Arterial Infusion Pump Placement
117. The Landmark Series: Appendiceal Primary Peritoneal Surface Malignancy
118. Lymph Node Metastases from Visceral Peritoneal Colorectal Metastases are Associated with Systemic Recurrence
119. ASO Visual Abstract: Lymph Node Metastases from Visceral Peritoneal Colorectal Metastases are Associated with Systemic Recurrence
120. Impact of Mitomycin-C-Induced Neutropenia after Hyperthermic Intraperitoneal Chemotherapy with Cytoreductive Surgery in Colorectal Cancer Patients with Peritoneal Carcinomatosis
121. ASO Author Reflections: Delayed Occurrence and Postoperative Risks of Mitomycin-C-Induced Neutropenia After Hyperthermic Intraperitoneal Chemotherapy
122. Risk of Intraoperative Hyperthermia and Outcomes in Adults Undergoing Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
123. ASO Author Reflections: Predicting Hyperthermia and Its Effect in Patients with Peritoneal Surface Malignancies
124. ASO Visual Abstract: Risk of Intraoperative Hyperthermia and Outcomes in Adults Undergoing Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
125. Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study
126. ASO Author Reflections: Bi-Directional Chemotherapy Using PIPAC Could Downstage Nonresectable Malignant Peritoneal Mesothelioma Patients to a Complete Resection
127. ASO Visual Abstract: Non-resectable Malignant Peritoneal Mesothelioma Treated with Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Plus Systemic Chemotherapy Could Lead to Secondary Complete Cytoreductive Surgery: A Cohort Study
128. Establishing Novel Molecular Subtypes of Appendiceal Cancer
129. ASO Author Reflections: Establishing Novel Molecular Subtypes of Appendiceal Cancer
130. ASO Visual Abstract: Establishing Novel Molecular Subtypes of Appendiceal Cancer